Article Text

Download PDFPDF
Global incidence proportion of intraventricular haemorrhage of prematurity: a meta-analysis of studies published 2010–2020
  1. Grace Y Lai1,
  2. Nathan Shlobin2,
  3. Roxanna M Garcia1,
  4. Annie Wescott3,
  5. Abhaya V Kulkarni4,5,
  6. James Drake4,5,
  7. Maria LV Dizon6,
  8. Sandi K Lam1,7
  1. 1 Neurological Surgery, McGaw Medical Center of Northwestern University, Chicago, Illinois, USA
  2. 2 Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
  3. 3 Galter Health Sciences Library, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
  4. 4 University of Toronto, Toronto, Ontario, Canada
  5. 5 Division of Neurosurgery, Hospital for Sick Children, Toronto, Ontario, Canada
  6. 6 Neonatology, Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, USA
  7. 7 Pediatric Neurosurgery, Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, USA
  1. Correspondence to Dr Grace Y Lai, Neurological Surgery, McGaw Medical Center of Northwestern University, Chicago, Illinois, USA; grace.y.lai{at}gmail.com

Abstract

Objective To investigate differences and calculate pooled incidence of any intraventricular haemorrhage (IVH), severe IVH (Grade III/IV, sIVH) and ventriculoperitoneal shunt (VPS) placement in preterm infants across geographical, health and economic regions stratified by gestational age (GA).

Design MEDLINE, Embase, CINAHL and Web of Science were searched between 2010 and 2020. Studies reporting rates of preterm infants with any IVH, sIVH and VPS by GA subgroup were included. Meta-regression was performed to determine subgroup differences between study designs and across United Nations geographical regions, WHO mortality strata and World Bank lending regions. Incidence of any IVH, sIVH and VPS by GA subgroups<25, <28, 28–31, 32–33 and 34–36 weeks were calculated using random-effects meta-analysis.

Results Of 6273 publications, 97 met inclusion criteria. Incidence of any IVH (37 studies 87 993 patients) was: 44.7% (95% CI 40.9% to 48.5%) for GA <25 weeks, 34.3% (95% CI 31.2% to 37.6%) for GA <28 weeks, 17.4% (95% CI 13.8% to 21.6%) for GA 28–31 weeks, 11.3% (95% CI 7.3% to 17.0%) for GA32–33 weeks and 4.9% (95% CI 1.4% to 15.2%) for GA 34–36 weeks. Incidence of sIVH (49 studies 328 562 patients) was 23.7% (95% CI 20.9% to 26.7%) for GA <25 weeks, 15.0% (95% CI 13.1% to 17.2%) for GA <28 weeks, 4.6% (95% CI 3.5% to 6.1%) for GA 28–31 weeks, 3.3% (95% CI 2.1% to 5.1%) for GA 32–33 weeks and 1.8% (95% CI 1.2% to 2.8%) for GA 34–36 weeks. Europe had lower reported incidence of any IVH and sIVH relative to North America (p<0.05). Proportion of VPS across all GA groups was 8.4% (95% CI 4.7% to 14.7%) for any IVH and 17.2% (95% CI 12.2% to 26.2%) for sIVH. Heterogeneity was high (I2 >90%) but 64%–85% of the variance was explained by GA and study inclusion criteria.

Conclusions We report the first pooled estimates of IVH of prematurity by GA subgroup. There was high heterogeneity across studies suggesting a need for standardised incidence reporting guidelines.

  • neonatology
  • neurosurgery
  • epidemiology

Data availability statement

Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplemental information. All raw data are available upon request to the corresponding author (grace.y.lai@gmail.com).

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplemental information. All raw data are available upon request to the corresponding author (grace.y.lai@gmail.com).

View Full Text

Footnotes

  • Contributors GYL is guarantor and conceptualised and designed the study, coordinated and supervised data collection, collected data, carried out the analyses, drafted the initial manuscript, and reviewed and revised the manuscript. NS collected data, carried out the initial analyses, and reviewed and revised the manuscript. AW conceptualised and designed the study, coordinated and supervised data collection, designed and performed the database search, and reviewed and revised the manuscript. RG, MD, AK, JD and SL conceptualised and designed the study, and critically reviewed the manuscript for important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.